Solid Biosciences Inc. Payments to Acquire Debt Securities, Available-for-sale
Solid Biosciences Inc. (SLDB) reported Payments to Acquire Debt Securities, Available-for-sale of $235.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- Solid Biosciences Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $151.94M, a 139.50% increase year-over-year.
- Solid Biosciences Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $83.46M, a 27.73% increase year-over-year.
- Solid Biosciences Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $23.92M, a 56.05% increase year-over-year.
- Solid Biosciences Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $83.19M, a 2.67% decline year-over-year.
- Solid Biosciences Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $235.89M, a 15.44% increase from fiscal 2024.
- Solid Biosciences Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $204.34M, a 74.01% increase from fiscal 2023.
- Solid Biosciences Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $117.43M, a 35.75% decline from fiscal 2022.
- Solid Biosciences Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $182.76M, a 29.39% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $151.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $235.40M 10-Q · filed 2026-08-06 | $259.32M derived: sum of 3 quarters · filed 2026-08-06 | $342.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $83.46M 10-Q · filed 2026-05-12 | $107.38M derived: sum of 2 quarters · filed 2026-05-12 | $190.57M derived: sum of 3 quarters · filed 2026-05-12 | $254.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $23.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $107.11M derived: sum of 2 quarters · filed 2026-03-19 | $170.55M derived: sum of 3 quarters · filed 2026-08-06 | $235.89M 10-K · filed 2026-03-19 |
| 2025-09-30 | $83.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $146.63M derived: sum of 2 quarters · filed 2026-08-06 | $211.97M 10-Q · filed 2025-11-03 | $227.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $63.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $128.78M 10-Q · filed 2026-08-06 | $144.11M derived: sum of 3 quarters · filed 2026-08-06 | $229.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $65.34M 10-Q · filed 2026-05-12 | $80.67M derived: sum of 2 quarters · filed 2026-05-12 | $166.14M derived: sum of 3 quarters · filed 2026-05-12 | $186.33M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $15.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $100.80M derived: sum of 2 quarters · filed 2026-03-19 | $120.99M derived: sum of 3 quarters · filed 2026-03-19 | $204.34M 10-K · filed 2026-03-19 |
| 2024-09-30 | $85.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $105.66M derived: sum of 2 quarters · filed 2025-11-03 | $189.01M 10-Q · filed 2025-11-03 | $203.62M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $20.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $103.54M 10-Q · filed 2025-08-12 | $118.15M derived: sum of 3 quarters · filed 2025-08-12 | $152.40M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $83.35M 10-Q · filed 2025-05-15 | $97.96M derived: sum of 2 quarters · filed 2025-05-15 | $132.21M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $14.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $48.87M derived: sum of 2 quarters · filed 2025-03-06 | $117.43M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $34.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $102.81M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $68.56M 10-Q · filed 2024-08-13 | |||
| 2022-12-31 | $19.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $70.07M derived: sum of 2 quarters · filed 2024-03-13 | $173.88M derived: sum of 3 quarters · filed 2024-03-13 | $182.76M 10-K · filed 2024-03-13 |
| 2022-09-30 | $50.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $154.27M derived: sum of 2 quarters · filed 2023-11-08 | $163.15M 10-Q · filed 2023-11-08 | $179.83M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $103.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $112.69M 10-Q · filed 2023-08-14 | $129.37M derived: sum of 3 quarters · filed 2024-03-13 | $205.57M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $8.88M 10-Q · filed 2023-05-11 | $25.56M derived: sum of 2 quarters · filed 2024-03-13 | $101.76M derived: sum of 3 quarters · filed 2024-03-13 | |
| 2021-12-31 | $16.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $92.88M derived: sum of 2 quarters · filed 2024-03-13 | $141.25M 10-K · filed 2024-03-13 | |
| 2021-09-30 | $76.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $124.57M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $48.37M 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $0.00 derived: sum of 3 quarters · filed 2023-03-23 | $401.00K 10-K · filed 2023-03-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $401.00K 10-Q · filed 2021-11-03 | $401.00K derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $401.00K 10-Q · filed 2021-08-16 | $401.00K derived: sum of 3 quarters · filed 2022-03-14 | $9.34M derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-03-31 | $401.00K 10-Q · filed 2021-05-14 | $401.00K derived: sum of 2 quarters · filed 2022-03-14 | $9.34M derived: sum of 3 quarters · filed 2022-03-14 | $16.48M derived: sum of 4 quarters · filed 2022-03-14 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $8.94M derived: sum of 2 quarters · filed 2022-03-14 | $16.08M derived: sum of 3 quarters · filed 2022-03-14 | $31.50M 10-K · filed 2022-03-14 |
| 2019-09-30 | $8.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $16.08M derived: sum of 2 quarters · filed 2020-11-05 | $31.50M 10-Q · filed 2020-11-05 | $57.07M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-06-30 | $7.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $22.56M 10-Q · filed 2020-08-06 | $48.14M derived: sum of 3 quarters · filed 2021-03-15 | $53.56M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-03-31 | $15.42M 10-Q · filed 2019-05-13 | $40.99M derived: sum of 2 quarters · filed 2021-03-15 | $46.41M derived: sum of 3 quarters · filed 2021-03-15 | $50.62M derived: sum of 4 quarters · filed 2021-03-15 |
| 2018-12-31 | $25.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $31.00M derived: sum of 2 quarters · filed 2021-03-15 | $35.20M derived: sum of 3 quarters · filed 2021-03-15 | $44.32M 10-K · filed 2021-03-15 |
| 2018-09-30 | $5.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $9.63M derived: sum of 2 quarters · filed 2019-11-12 | $18.74M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $4.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $13.32M 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $9.12M 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | $18.90M 10-K · filed 2020-03-12 | |||
| 2016-12-31 | $25.70M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |